F10 and cancer: Cohen and colleagues compared propensity score (model based on age, bleed location, history of atrial fibrillation, venous thromboembolism, stroke, renal dysfunction, and cancer)–adjusted cohorts of andexanet alfa- and PCC-managed FXa inhibitor major bleeding patients [24].